Systematic review of implementation quality of non-pharmacological stuttering intervention trials for children and adolescents.

Autor: Hofslundsengen H; Western Norway University of Applied Sciences, Faculty of Education, Arts and Sports, box 131, 6856 Sogndal, Norway. Electronic address: Hilde.hofslundsengen@hvl.no., Kirmess M; University of Oslo, Department of Special Needs Education, Mail Box 1140 Blindern, 0318 Oslo, Norway; Sunnaas Rehabilitation Hospital, Bjørnemyrveien 11, 1453 Bjørnemyr, Norway. Electronic address: melanie.kirmess@isp.uio.no., Guttormsen LS; University of Oslo, Department of Special Needs Education, Mail Box 1140 Blindern, 0318 Oslo, Norway. Electronic address: l.s.guttormsen@isp.uio.no., Næss KB; University of Oslo, Department of Special Needs Education, Mail Box 1140 Blindern, 0318 Oslo, Norway. Electronic address: k.a.b.nass@isp.uio.no., Kefalianos E; University of Melbourne, Department of Audiology & Speech Pathology, Faculty of Medicine, Dentistry and Health Sciences, Level 2, 550 Swanston Street, Carlton, 3052, Australia. Electronic address: elaina.kefalianos@unimelb.edu.au.
Jazyk: angličtina
Zdroj: Journal of fluency disorders [J Fluency Disord] 2022 Mar; Vol. 71, pp. 105884. Date of Electronic Publication: 2021 Nov 10.
DOI: 10.1016/j.jfludis.2021.105884
Abstrakt: Purpose: This narrative systematic review in line with PRISMA guidelines aims to investigate the implementation quality of previously published group comparison clinical trials of stuttering interventions for children and adolescents (under age 18 years).
Methods: We searched for publications in the databases Eric, PsychInfo, PubMed and Web of Science using the search terms 'stutt*' or 'stamm*'and 'intervention', 'trial' or 'treatment'. We reviewed the implementation elements reported in studies and how these elements were used to report intervention outcomes.
Results: 3,017 references published between 1974-2019 were identified. All references were screened for eligibility using predefined selection criteria resulting in 21 included studies. The implementation quality details reported varied between studies. Existing studies most commonly lacked details about the support system provided to SLPs administering the interventions and monitoring of treatment fidelity both in the clinical setting and in the home environment. Support systems for participant's parents and treatment dosage were generally well reported. Dosage was the most common implementation quality element considered in analyses of treatment effect and within discussions of findings.
Conclusion: Findings highlight the need for future clinical trials of stuttering interventions to closely adhere to systematic guidelines for reporting implementation quality to ensure reliability of trial outcomes. A checklist for reporting clinical trials of non-pharmacological stuttering interventions is proposed.
(Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: